Jump to content

2CBecca

From Wikipedia, the free encyclopedia

2CBecca
Clinical data
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • 4-(4-bromo-2,5-dimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline
Chemical and physical data
FormulaC17H18BrNO2
Molar mass348.240 g·mol−1
3D model (JSmol)
  • COc1cc(Br)c(cc1C1CNCc2c1cccc2)OC
  • InChI=1S/C17H18BrNO2/c1-20-16-8-15(18)17(21-2)7-13(16)14-10-19-9-11-5-3-4-6-12(11)14/h3-8,14,19H,9-10H2,1-2H3
  • Key:LRHOKFHXSNZVLA-UHFFFAOYSA-N

2CBecca, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the phenethylamine family.[1][2] It is a cyclized phenethylamine derivative of the serotonergic psychedelic 2C-B, in which the ethylamine side chain has been replaced with a 1,2,3,4-tetrahydroisoquinolinyl moiety.[1][2] The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 39–71 nM and 267–850 nM, respectively).[1][2][3][4] 2CBecca was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.[2]

See also

[edit]

References

[edit]
  1. ^ a b c Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 837–839, 866–867. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. ^ a b c d Braden MR (2007). Towards a Biophysical Understanding of Hallucinogen Action (Ph.D. thesis). Purdue University. ProQuest 304838368.
  3. ^ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  4. ^ Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, et al. (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC 3547484. PMID 23336049.
[edit]